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Evaluation of Abciximab on Dissolution of Newly Formed Thrombus
Developed During Coronary Angioplasty and Stenting
CHUAN-YU GAO, ROBERT WHITBOURN*, ANDREW MACISAAC*, PATRICIA FOX*, MICHAEL JELINEK*
From the Department of Cardiology, Henan Provincial People's Hospital, China; and *the Department of Cardiology,
St. Vincent's Hospital Melbourne, Fitzroy 3065, Australia

GAO ET AL.: Evaluation of Abciximab on Dissolution of Newly Formed Thrombus Developed During Coronary
Angioplasty and Stenting. The study observed the effect on thrombus of the glycoprotein IIb/IIIa antagonist abciximab.
We studied retrospectively 72 patients, who had definite or possible thrombus that was newly developed during
cardiac intervention. They were given abciximab, 0.25 mg/kg body weight intravenous bolus, followed by 12 hours
intravenous infusion at 0.125 µg/min/kg body weight, maximum 10 µg/min (standard ReoPro protocol) or just given
abciximab bolus. The result showed that the combination of abciximab and balloon dilation decreased thrombus
score (2.29 ± 1.46 vs 1.29 ± 1.37 in PTCA group, p<0.0005; 1.82 ± 1.32 vs 0.33 ± 0.81 in Stenting group, p<0.0005);
TIMI flow got a good restoration (1.04 ± 0.79 vs 2.50 ± 0.76 in PTCA group, p<0.0005; 1.38 ± 0.70 vs 2.96 ± 0.20
in Stenting group, p<0.0005). Q-MI, Non-Q-MI, death, revascularization and CABGs in hospital were not different
between PTCA and Stenting groups and between "standard ReoPro" and "ReoPro bolus only" (p>0.05), but patients
who were treated using standard ReoPro protocol had more bleeding complications (p<0.05) and prolonged hospital
stay (5.59 ± 3.91days vs 2.56 ± 0.73 days, p<0.05) than the patients did who had only abciximab bolus. So "ReoPro
bolus only" may have same clinical efficacy like "standard ReoPro protocol" does and has less bleeding complication.
(J HK Coll Cardiol 2000;8:138-144)
Abcixmab (ReoPro), complication, coronary angioplasty, coronary stenting, coronary thrombosis, prognosis

µ
±
±

±
±

±
±

±

±

Address for reprints: Dr. Chuan-Yu Gao
the Department of Cardiology, Henan Provincial People's Hospital,
7 Weiwu Road, Zhengzhou 450003, China.
Tel: (86) 371 5972157, Fax: (86) 371 5964376
Received April 5, 2000; revision accepted June 16, 2000

138

July 2000

J HK Coll Cardiol, Vol 8

GAO ET AL.

Introduction

intervention (two patients). All patients gave informed
consent.

Acute thrombus and abrupt closure during and
after coronary intervention procedures are major
ischaemic complication. It has been reported that the
rate of abrupt occlusion is about 0.5-2%. 1,2 This is
responsible for the initiation of the coagulation cascade
and, at the same time, of platelet adhesion and
activation, finally resulting in the formation of a platelet
rich thrombus following percutaneous transluminal
coronary angioplasty (PTCA) and Stenting procedure.
This process is quite quick, probably new thrombus may
be formed in a couple of minutes. A couple of studies
have showed that prophylactically GP IIb/IIIa
antagonists-abciximab (ReoPro) with standard-dose,
weight-adjusted heparin (100 u/kg) or low-dose, weightadjusted heparin (70 u/kg) before cardiac intervention
can substantially reduce the rate of ischaemic
complications in particular patients with high risk
factors, before, during and after PTCA.3-6 However,
the usefulness of abciximab in acute thrombus
developing in the catheter lab has never been evaluated
completely.2,7 In this study, we evaluated and compared
the efficacy of abciximab on acute platelet-rich
thrombus and in-hospital outcome of the patients in
whom intra-coronary thrombus was developed during
the cardiac intervention (only PTCA or Stenting
procedure) after standard ReoPro protocol or only
ReoPro bolus was administered.

Methods
Study Population
We retrospectively studied all angioplasty
patients with acute intra-coronary thrombosis
developing in catheter lab from April 1996 to April
1998. The patients undergoing elective or urgent
percutaneous coronary revascularization with a device
approved by the Food and Drug Administration were
eligible for inclusion if they had a target lesion with
stenosis of at least 70% of the diameter of the vessel.
Exclusion criteria were that patients had previously new
formed thrombus angiographically in coronary target
lesion before cardiac intervention started, for example,
acute myocardial infarction with thrombus (two
patients) and acute coronary occlusion after cardiac
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Study Protocol
All patients were given 150-300 mg of Aspirin
orally at least one day prior to the procedure for elective
and 300 mg of Aspirin orally at least 1 hour for urgent
cases and daily was administered thereafter. Ticlopidine
250 mg was given twice daily for 1-3 days before
revascularization and 3 weeks after revascularization.
A standard-dose bolus of heparin was given (10,000 u)
before the interventional hardware went into the
coronary artery with additional weight-adjusted boluses
calculated according to an algorithm intended to achieve
and maintain an activated clotting time (ACT) of at
least 300 seconds. If a new thrombus was seen
angiographically during the procedure, a bolus of
abciximab of 0.25 mg/kg body weight was administered
10-20 minutes before further inflation of the balloon or
activation of the device, followed by an infusion of
0.125 µg/kg/m (maximum, 10 µg/m) for 12 hours
(ReoPro standard protocol) or just abciximab bolus was
given. The protocol recommended that heparin be
discontinued immediately after interventional procedure
and that vascular sheath be removed when the ACT was
170 seconds or less, and then intravenous heparin be
started 2 hours post sheath removal for over-night at
the rate of 10 units/kg/h in two groups. Implantation of
stents was discouraged and was reserved as means of
maintaining patency after manifest of threatened abrupt
closure in 1996, but was encouraged from 1997-1998.
Specific guidelines for sites of vascular access stressed
the early removal of sheaths, compression of the femoral
access site for 30 minutes to achieve haemostasis after
removal of the vascular sheath, and strict bed rest and
immobilisation of limbs for 6-8 hours after removal of
sheaths. Algorithms were provided for the management
of uncontrolled bleeding, urgent coronary artery bypass
surgery, and thrombocytopenia, and it was
recommended that red-cell transfusion be administered
according to the clinical guidelines.

Data Collection
For each patient, routine demographic and
clinical data, procedural result and in-hospital
complications were prospectively entered into a
computerised database. All data were verified by
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Result

retrospective review of patient records and coronary
angiograms.

Patients Demographics
Angiographic Analysis
Angiograms were analysed before the procedure,
just before the administration of abciximab and after
the procedure. Cine angiograms of patients with
thrombus developing in the catheter lab were
interpreted and verified by two experienced cardiac
interventionalists (Dr. Robert Whitbourn and Andrew
MacIsaac) for morphologic features similar to those
used in the American College of Cardiology/American
Heart Association guideline,8 visual determination of
coronary thrombus score was performed using the
previously reported TIMI scale of 0 to 4: 0=no
thrombus; 1=haziness; 2=definite thrombus <1/2
vessel diameter; 3=definite thrombus 1/2 to 2 vessel
diameter; 4=definite thrombus >2 vessel diameters.
9,10
New development of thrombus was defined as an
increase in the coronary thrombus grade by at least
one level during the course of the angioplasty
procedure. Visual determination of coronary flow
performed using the TIMI flow scale: 0=no flow past
the lesion; 1=flow past the lesion but not filling the
entire vessel; 2=flow pass the lesion filling the entire
vessel, but slower than that of non-affected vessels;
3=normal flow.11

Demographic data from the study patients are
shown in Table 1. A high proportion of patients were
men and had hypertension or hypercholesterolemia.
Most patients had been admitted with the acute
ischaemic syndromes of unstable angina in both groups
of stenting or PTCA (56% and 51% respectively).

Lesion Characteristics and Thrombosis
As shown in Table 1 and Table 2, most
procedures were performed in native coronary vessels
(87.5%) with about half of these vessels in the left
anterior descending coronary artery (LAD, 47.2%). The
majority of target lesions were judged to be of high
clinical risk and high lesion risk. Some degree of intralesion thrombus was noted before the procedure.
Incidence of definite thrombus in both PTCA and
Stenting groups was 2.87 % and 1.88% respectively
(p>0.05), incidence of possible thrombus was 3.72%
and 4.69% respectively (p>0.1), the incidence of
thrombus combining definite with possible was 6.59%
and 6.57% respectively (P>0.9). Prevalence of thrombus
in vessel sequence was Graft >LAD>RCA>LCX in both
groups of PTCA and Stenting (but all p>0.25). Here
did not see significantly statistical difference among
different kind of stents (X2=4.729, p>0.25).

Study End Points and Definition
All clinical data were obtained before patients
were discharged or transferred to thoracic cardiac
department for coronary artery bypass grafting
(CABG). Success was defined as a final diameter
stenosis of less than 50% in the absence of any major
complication. Major complications were emergency
artery bypass surgery, Q-wave myocardial infarction
(Q-MI) , death and target lesion revascularization.
Significant Q-waves in two or more continuous
electrocardiographic leads was defined as Q-wave
myocardial infarction. Non-Q MI was defined as at
least two fold increase in serum level of cardiac
creatine phosphokinase (CPK-MB).

Data Management and Statistical Analysis

All means were expressed with ±1 SD. The
student t test was used for numerical variables and the
chi square test was used for categorical data.
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Procedure Characteristics
44 patients in the stenting group underwent a
predilation before deployment of stents and 5 cases had
primary stenting without predilation. When a new
developing thrombus was identified, we performed a
balloon post-dilation 10 minutes after ReoPro was
given. In balloon PTCA group, all patients underwent
redilation when a new developing thrombus was present
after ReoPro was given for at least 10 minutes. As shown
in Table 3, a significant improvement occurred in all
three values.

Acute Result
In the stenting group, no-reflow phenomena
occurred in one patient after a 3.0 by 13 ACS Duet stent
was deployed in the native LAD, and distal emboli
occurred in 2 cases when new thrombus were identified
(in native LAD and RCA respectively). The TIMI flow
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Table 1. Demographics and lesion characteristics of 72 study patients with definite or possible thrombus

Sex M/F
Ages (years)
Risk Factors
Hypertention
Diabetes mellitus
High Cholesterol
Family History
Smoking History
Indication
Unstable Angina
Stable Angina
Post-AMI
Intervention Vessel
LAD
LCX
RCA
Graft
ACC/AHA Type
A
B
C
Vessel Diameter(mm)

PTCA group (%)
n=23
15/8 (65/35)
63.6±12.7

Stenting group (%)
n=49
38/11 (77/23)
61.2±11.6

p value

14 (60.9)
5 (21.7)
13 (56.5)
14 (60.9)
9 (39.1)

32 (65.3)
12 (24.5)
32 (65.3)
31 (63.3)
22 (44.9)

NS
NS
NS
NS
NS

13 (56.5)
7 (30.4)
3 (13.0)

25 (51.2)
19 (38.8)
5 (10.2)

NS
NS
NS

11 (47.8)
1 (4.3)
8 (34.8)
6 (26.1)

23 (46.9)
8 (16.3)
15 (30.6)
3 (6.1)

NS
NS
NS
<0.05

0 (0.0)
7 (27.0)
19 (73.0)
3.13±0.48

0 (0.0)
16 (32.7)
33 (67.4)
3.06±0.40

NS
NS
NS
NS

NS
NS

Note: NS=no statistically significance

Table 2. The treated vessels, the used stents and the thrombus developed during cardiac intervention

PTCA vessel
LAD
RCA
LCX
Graft
Stented vessel
LAD
RCA
LCX
Graft
Used stents
Nir stent
ACS ML stent
AVE micro II
J&J PS
Others

Number of
treated vessels
349
132 (37.8)
117 (33.5)
76 (21.78)
24 (6.88)
746
302 (40.48)
253 (33.91)
149 (19.97)
42 (5.63)
939
734 (78.17)
79 (8.41)
89 (9.48)
17 (1.81)
20 (2.13)

Thrombus
present (%)
10 (2.87)
6 (4.55)
1 (0.85)
0 (0.00)
3 (12.5)
14 (1.88)
6 (1.98)
3 (1.19)
3 (2.01)
2 (4.76)
14 (1.49)
9 (1.23)
0 (0.00)
5 (6.33)
0 (0.00)
0 (0.00)

Thrombus
possible (%)
13 (3.72)
7 (5.30)
4 (3.40)
1 (1.32)
1 (4.17)
35 (4.69)
16 (5.30)
13 (5.14)
4 (4.76)
2 (4.76)
35 (3.73)
24 (3.26)
6 (7.59)
4 (4.49)
0 (0.00)
1 (5.00)

Thrombus
present+possible (%)
23 (6.59)
13 (9.85)
5 (4.27)
1 (1.32)
4 (16.67)
49 (6.57)
22 (7.28)
16 (6.32)
7 (4.69)
4 (9.52)
49 (5.22)
33 (4.50)
6 (7.59)
9 (10.11)
0 (0.00)
1 (5.00)

Note:
1. LAD=left descending artery; RCA=right coronary artery; LCX=left circumflex artery; PTCA=percutaneous transluminal coronary
angioplasty
2. Prevalence of thrombosis during interventional procedure was similar between PTCA and Stenting(thrombus present and possible:
6.59% vs 6.57%, p>0.9, X2=0.0025; thrombus present: 2.87% vs 1.88%, p>0.25, X2=0.6745; thrombus possible: 3.72% vs 4.69%,
p>0.1, X2=0.1379)
3. Prevalence of coronary artery subject to thrombosis was similar too between PTCA and Stenting. The sequence was Graft >LAD >RCA>
LCX ,but all p>0.25
4. Prevalence in different stents subject to thrombosis in catheter lab was no significant difference, p>0.25, X2=4.729
5. PTCA patients=339; Stented patients=713; The number of used stents=939
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of the patients was all restored to Grade III 10 minutes
after ReoPro was given. Vein graft stenting procedures
in two patients, were completed successfully under the
support of IABP(intra-aortic balloon pump). Four
patients with no-reflow phenomena (one in LAD, one
in RCA, two in vein grafts) were noticed in balloon
PTCA group when new thrombus was identified. The
TIMI flow recovered from I to II 10 minutes after
ReoPro was given and at the end of the procedure. One
patient who had three vessels disease and used only
ReoPro bolus required emergent surgery directly from
the catheter lab under the support of IABP after PTCA
failed; No patients experienced procedural Q-wave
myocardial infarction. In all patients with identified new
thrombus, the thrombus only partially blocked target

vessels; only one patient, whose saphenous graft
underwent balloon PTCA, formed a great longitudinal
blood clot that resulted a TIMI grade I flow. His TIMI
flow grade was still TIMI I when the procedure finished
and he left catheter lab under the support of IABP. No
patients developed totally abrupt occlusion due to new
formed thrombus, dissection or intimal flaps. So, the
procedure successful rate in catheter lab was 100% in
stenting and 96% in PTCA group .

In-hospital Complication and Clinical Success
(Table 4)
During the remaining hospital course, 40 patients
received standard ReoPro treatment (25 cases stenting
and 15 cases PTCA), no patients had acute Q-wave

Table 3. Changes of target vessel stenosis, thrombus score and TIMI flow grade of 72 patients

Stenosis (%)
Thrombus score
TIMI flow grade

before procedure
PTCA
Stenting
93.3±8.2
88.4±9.3
1.4±1.8
1.0±1.7
1.04±0.79
1.38±0.70

before ReoPro given
PTCA
Stenting
53.0±32.2* 44.8±27.4*
2.3±1.5*
1.8±1.3*
1.50±0.91* 1.71±0.62*

at end of procedure
PTCA
Stenting
21.7±14.3*
4.4±8.7*
1.3±1.4∆
0.3±0.8*
2.50±0.76* 2.96±0.20*

Note:
1. Data presented are mean+1SD; "before ReoPro given" means that new thrombus was identified at this stage; TIMI flow means
"Thrombolysis in myocardiac infarction" flow.
2. Compared to "before procedure", *: p<0.05; ∆: P>0.05, but, when comparing to "before ReoPro given", p<0.05;

Table 4. In-hospital complication of 72 patients with definite or possible thrombus in different subgroups

Any access site bleed
Access site haematoma
Pericardial bleed
Thrombocytopenia
Blood transfusion
Stroke
Revascularisation in 24h
CABGs
Non-Q-MI
Q-MI
Death
Hospital stay (days)

N=49
Stenting
26 (53.06)
5 (8.16)
1 (2.04)
1 (2.04)
2 (4.08)
0
0
0
2 (4.08)
0
0
4.43±2.45

N=23
PTCA
10 (43.48)
1 (4.34)
0
0
0
1 (4.34)
0
1 (4.34)
2 (8.68)
0
0
3.75±1.91

N=40
Standard ReoPro
21 (52.50)
5 (12.50)
1 (2.50)
1 (2.50)
2 (5.00)
1 (2.5)
0
0
2 (5.0)
0
0
5.59±3.91

N=32
ReoPro bolus only
15 (46.88)
1 (3.12)
0
0
0
0
0
1 (3.12)
2 (6.24)
0
0
2.56±0.73

Note:
1. Any access site bleeding and main in-hospital complication (Revascularization, CABGs, Q-MI, Death), no different between PTCA and
Stenting and between "Standard ReoPro" and "ReoPro bolus only" (all p>0.05)
2. Main bleeding complication (access site haematoma, pericardial bleeding, thromocytopenia, blood transfusion), no different between
PTCA and Stenting (X2=2.56, p>0.1). But "Standard ReoPro" group had litter bit more or life-threatening bleeding complication (X2=
4.07, p<0.05)
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myocardial infarction, CABG; but in these patients, one
patient who had LAD stenting had life-threatening
pericardial bleeding 3 hours post-procedure with
pericardial tamponade; one patient who had left internal
mammary artery PTCA had small stroke; 6 patients had
significant access site bleeding and haematoma (5
patients had stents and 1 had PTCA), but haematomas
were all less than 10 centimetres and did not need
surgical repair. In another 2 patients, who had vein graft
stenting and PTCA respectively, they required blood
transfusion and 1 experienced thrombocytopenia;
Average hospital stay was 5.59±3.91 days. Another 32
patients ( 24 cases of stenting and 8 cases of PTCA)
just used ReoPro bolus injection and low-dose weight
adjusted heparin infusion over-night post-sheath
removal 2 hours; In these 32 patients, only one patient
who had left circumflex artery PTCA had small access
site haematoma. No patients experienced Q-wave MI,
acute closure, CABG, revascularisation or death in
hospital; Average hospital stay was 2.56±
0.73 days. So, overall clinical success was 100% (49/
49) in stenting group, 96% (22/23) in PTCA group,
100% (40/40) in ReoPro standard protocol group,
96.8% (31/32) in ReoPro bolus only group.

Discussion
Abrupt occlusion of the stented vessels occurred
in 0.5-2.0%, and the cause of 80% was thrombsis in the
coronary artery,1,2 despite pre-existing use of combined
antiplatelet therapy with aspirin and ticliopidine. The
current view about new thrombus focuses on platelet
activation, and thrombosis.1-3,12 When interventional
devices compress, squash or dilate diseased vessel
segments, the coagulation cascade is activated.
Activated platelets expose the phospholipid surface and
IIb/IIIa platelet glycoprotein receptor on which platelet
and fibrinogen combine together and form new
thrombus. Fortunately, a new drug, GP IIb/IIIa receptor
antagonist, abciximab (ReoPro), has recently showed
its ability to prevent the thrombosis3-6 and dissolve
thrombus.2,7,12
Despite the documented clinical efficacy of the
prophylactic use of abciximab during coronary
angioplasty from EPIC study, EPILOG and CAPTURE
study, concerns regarding the cost of its use and bleeding
complication still exist.13 Recently, we also noticed that
rescue utilisation of abciximab when coronary abrupt
J HK Coll Cardiol, Vol 8

closure occurred, produced a satisfactory clinical
benefit.7 We also achieved similar clinically efficacy
in both PTCA and stenting groups. Abciximab can
effectively restore the TIMI flow grade and decreases
thrombus score in these patients who had a newly
formed thrombus in the catheter lab. Rapid distal runoff in patients with distal embolisation and no-reflow
state will be reestablished within minutes after treatment
with the abciximab (Table 3).14,15
The previous studies have showed that both
ReoPro standard protocol plus standard-dose, weightadjusted heparin or low-dose, weight-adjusted heparin
achieved the same clinical effectiveness during hospital,
at 3 months and 6 months follow-up,4,5 but bleeding
complication was more frequent.4,5,16 As result of cost,
bleeding complications and efficacy of abciximab, some
doctors modified previous standard abciximab strategy.
In the present study, 40 patients received abciximab
standard dose regimen (bolus + infusion). In these
patients, pericardial tamponade occurred in one case,
thrombocytopenia in one case, significant access site
haematoma and bleeding in 5 cases. In another 32
patients, who only received ReoPro bolus injection, no
significant bleeding complications were noticed (Table
4); only one patient had urgent CABGs directly from
catheter lab after PTCA failed, but the reason for CABG
was not due to intra-coronary thrombosis, because the
patient had multi-vessel coronary disease and bad left
ventricular function. Both treatments all achieved the
same clinical result.

Conclusion
Dissolution of thrombus and restoration of TIMI
flow were readily achieved after administration of
abciximab when the development of new thrombus was
identified in both PTCA and stenting groups. Both
strategies of abciximab bolus only and standard
abciximab strategy (bolus + infusion) have the same
satisfactory clinical efficacy in hospital, but the patients
with standard abciximab protocol have slightly more
or life-threatening bleeding complication.

Limitation
This study was a retrospective study, not a double
blind clinical study. The strategy of standard abciximab
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or only abciximab bolus depended completely on the
various treating doctors. Although we achieved a
satisfactory clinical result and less bleeding
complications in abciximab bolus group, we can not be
sure that the strategy has the same long term outcome
as "standard abciximab protocol".
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